Description:
Lubiprostone, also known as RU-0211, is a new agent indicated for the treatment of patients with chronic constipation. It is a member of a new class of compounds called prostones. It was initially approved by the U.S. Food and Drug Administration (FDA) in 2006. Nonclinical studies demonstrated that lubiprostone exerts its effects on type-2 chloride channels (ClC-2), enhancing fluid secretion into the intestinal lumen.
- Molecular Weight: 390.46
- Molecular Formula: C20H32F2O5
Purity: ≥98%
Canonical SMILES:
O=C(O)CCCCCCC1C(=O)CC2OC(O)(CCC21)C(F)(F)CCCC
InChI:
InChI=1S/C20H32F2O5/c1-2-3-11-19(21,22)20(26)12-10-15-14(16(23)13-17(15)27-20)8-6-4-5-7-9-18(24)25/h14-15,17,26H,2-13H2,1H3,(H,24,25)/t14-,15-,17-,20-/m1/s1
InChIKey: WGFOBBZOWHGYQH-MXHNKVEKSA-N
- Boiling Point: 532.3±50.0 °C at 760 Torr
- Solubility: Soluble in Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
- Appearance: Off-white Solid
- Application: Chloride channel agonists
- Storage: Store at -20°C
Synonyms:
Prostan-1-oic acid, 11,15-epoxy-16,16-difluoro-15-hydroxy-9-oxo-, (11α,15R)-; (11α,15R)-11,15-Epoxy-16,16-difluoro-15-hydroxy-9-oxoprostan-1-oic acid; 7-[(1R,3R,6R,7R)-3-(1,1-Difluoropentyl)-3-hydroxy-8-oxo-2-oxabicyclo[4.3.0]non-7-yl]heptanoic acid; 7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentan-1-yl)-2-hydroxy-6-oxooctahydroxypenta[b]pyran-5-yl]heptanoic acid; Bicyclic lubiprostone; Cyclopenta[b]pyran-5-heptanoic acid, 2-(1,1-difluoropentyl)octahydro-2-hydroxy-6-oxo-, (2R,4aR,5R,7aR)-; Lubiprostone; Lubiprostone hemiketal; RU 0211; SPI 0211
More details are to be found on supplier website
